TMEM191B-like: A Transmembrane Protein with Potential as A Drug Target and Biomarker

Target Name: TMEM191B

NCBI ID: G728229

TMEM191B

Other Name(s): transmembrane protein 191B-like | Transmembrane protein 191B | T191B_HUMAN | transmembrane protein 191B

TMEM191B-like: A Transmembrane Protein with Potential as A Drug Target and Biomarker

TMEM191B-like is a transmembrane protein that is expressed in various tissues and cells throughout the body. It is characterized by a unique domain structure that is similar to that of transmembrane proteins, such asTMEM120, TMEM44, and TMEM182. TMEM191B-like is expressed in a variety of tissues, including the brain, heart, liver, and pancreas, and has been shown to play a role in several cellular processes, including cell signaling, inflammation, and metabolism.

One of the key features of TMEM191B-like is its ability to form a homotetrically arranged transmembrane structure. This is achieved through the presence of a unique transmembrane segment, known as the N-terminal region, which contains a conserved amino acid sequence that is involved in the formation of a transmembrane ternary structure. The N-terminal region is followed by a variable-length cytoplasmic tail, which is also involved in the formation of the transmembrane structure.

The unique structure of TMEM191B-like has led to its potential as a drug target. Several studies have shown that TMEM191B-like can be targeted by small molecules, including inhibitors of tyrosine kinase activity and modulators of ion channels. Additionally, TMEM191B-like has been shown to play a role in several diseases, including neurodegenerative diseases, diabetes, and cancer.

One of the potential benefits of targeting TMEM191B-like is its potential to modulate ion channels that are involved in the regulation of ion transport and cell signaling. This can lead to a variety of potential therapeutic effects, including the inhibition of neurotransmitter release, the modulation of cellular signaling pathways, and the regulation of ion homeostasis.

In addition to its potential as a drug target, TMEM191B-like has also been shown to be involved in several cellular processes that are important for normal cellular function. For example, TMEM191B-like has been shown to play a role in the regulation of cell adhesion, which is critical for the maintenance of tissue structure and the development of tissues. Additionally, TMEM191B-like has been shown to be involved in the regulation of cell signaling pathways, including the TGF-β pathway, which is involved in the regulation of cell growth and differentiation.

Another potential therapeutic application of TMEM191B-like is its use as a biomarker for the diagnosis and monitoring of disease. Several studies have shown that TMEM191B-like is expressed in a variety of tissues and cells, including those affected by neurodegenerative diseases, diabetes, and cancer. This makes it a potential biomarker for these diseases, as the expression of TMEM191B-like may be sensitive to changes in the levels of this protein in the affected tissue.

In conclusion, TMEM191B-like is a unique and highly conserved transmembrane protein that is expressed in a variety of tissues and cells throughout the body. Its unique structure and ability to form a transmembrane structure make it a potential drug target, and its involvement in several cellular processes makes it a potential biomarker for the diagnosis and monitoring of disease. Further research is needed to fully understand the role of TMEM191B-like in cellular processes and its potential as a therapeutic agent.

Protein Name: Transmembrane Protein 191B

The "TMEM191B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM191B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets